Skip to content
AnalystLens

Leidos Holdings 8-K Report, Financial Results (May 6, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed May 6, 2025
Period End
May 6, 2025
Security
LDOS
In the record · 2016–202610-K1210-Q338-K130

LDOS filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Material agreement8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed May 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Leidos Holdings, Inc. (NYSE: LDOS) reported first-quarter fiscal 2025 results for the quarter ended April 4, 2025, with revenues of $4.25 billiona, up 7% year-over-year, and net income of $365 million, or $2.77 per diluted share.

Net income rose 29% and diluted EPS rose 34% year-over-year. Adjusted EBITDA was $601 millionb, up 23%, with a 14.2% margin versus 12.3% a year earlier. Non-GAAP diluted EPS was $2.97, up 30%.

Management attributed the profitability gains primarily to increased volumes on managed health services programs and improved program execution and cost control. The company reaffirmed its fiscal 2025 guidance, including revenues of $16.90 to $17.30 billionc, an adjusted EBITDA margin in the mid-to-high 12% range, non-GAAP diluted EPS of $10.35 to $10.75, and operating cash flow of approximately $1.45 billion. Cash generation was weaker in the quarter, with operating cash flow of $58 million and free cash flow (non-GAAP) of $36 million.

The company issued $1.0 billiond of senior unsecured notes due 2032 and 2035, used proceeds to retire $500 million of notes due May 2025, and repurchased $500 million of stock under an accelerated share repurchase agreement. Cash and cash equivalents were $842 million and debt totaled $5.1 billion as of April 4, 2025. Leidos also agreed to acquire a cyber platform developer for a preliminary price of $300 million, with closing expected in the second quarter of 2025.

The filing also includes a revised backlog policy, effective in fiscal 2025, that adds estimated future revenue on expected sole source IDIQ task orders. Under this policy, backlog at the end of the quarter was $46.3 billion, of which $7.3 billion was funded, and net bookings were $2.1 billion, a book-to-bill ratio of 0.5. Exhibit 99.2 recasts backlog, bookings and book-to-bill for prior periods under the new policy.

Key Highlights

  1. Revenues of $4.25 billion, up 7% year-over-year; net income of $365 million, or $2.77 per diluted share
  2. Adjusted EBITDA of $601 million, up 23% year-over-year, with a 14.2% margin versus 12.3% in the prior-year quarter
  3. Non-GAAP diluted EPS of $2.97, up 30% year-over-year; fiscal 2025 guidance reaffirmed
  4. Operating cash flow of $58 million and non-GAAP free cash flow of $36 million in the quarter
  5. Issued $1.0 billion of senior unsecured notes (2032 and 2035) and repurchased $500 million of stock via accelerated share repurchase
  6. Agreed to acquire a cyber platform developer for a preliminary price of $300 million, expected to close in Q2 2025
  7. Backlog of $46.3 billion under a revised policy that includes estimated sole source IDIQ task orders; net bookings of $2.1 billion

Frequently Asked Questions

  1. Did Leidos reaffirm its fiscal 2025 guidance?

    Yes. Leidos reaffirmed its fiscal 2025 guidance: revenues of $16.90 to $17.30 billion, an adjusted EBITDA margin in the mid-to-high 12% range, non-GAAP diluted EPS of $10.35 to $10.75, and operating cash flow of approximately $1.45 billion.

  2. Why was first-quarter cash flow weak relative to earnings?

    Operating cash flow was $58 million against net income of $365 million. The filing shows a $246 million increase in receivables, a $148 million decrease in accrued payroll and employee benefits, and a $72 million reduction in accounts payable and accrued liabilities, partly offset by a $121 million income tax receivable/payable change. Management cited strong EBITDA and collections performance, and DSO was 62 days, in line with the prior year.

  3. What changed in Leidos' backlog reporting?

    Beginning in fiscal 2025, Leidos expanded its backlog policy to include estimated future revenue on task orders expected under sole source IDIQ contracts. Exhibit 99.2 recasts backlog, bookings and book-to-bill for prior periods. For example, recast net bookings were $7.4 billion for the three months ended January 3, 2025, and the recast book-to-bill ratio was 1.7 for that quarter.

  4. What drove the improvement in profitability?

    Management attributed the increase in profitability primarily to higher volumes on managed health services programs and improved program execution and cost control across the company. Health & Civil operating income margin rose to 23.2% from 18.5%, and Defense Systems margin rose to 6.7% from 4.4%.

  5. How is Leidos funding its acquisition and share repurchases?

    In the quarter, Leidos issued $500 million of 5.40% senior unsecured notes due 2032 and $500 million of 5.50% notes due 2035. Proceeds were used to retire $500 million of notes due May 2025 and repurchase $500 million of stock under an accelerated share repurchase agreement. The filing states cash and equivalents of $842 million and debt of $5.1 billion as of April 4, 2025.